How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions

Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Greene, Paul [verfasserIn] Kaiser, Matthew

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2019

Schlagwörter:	Therapeutic Use Exemptions World Anti-Doping Code International Standard for Therapeutic Use Exemptions Ultimate Fighting Championship Retroactive TUE Prospective TUE Fairness

Anmerkung:	© T.M.C. Asser Instituut 2019

Übergeordnetes Werk:	Enthalten in: The international sports law journal - Berlin : Springer, 2002, 19(2019), 1-2 vom: 12. Juli, Seite 29-37
Übergeordnetes Werk:	volume:19 ; year:2019 ; number:1-2 ; day:12 ; month:07 ; pages:29-37

Links:	Volltext

DOI / URN:	10.1007/s40318-019-00154-7

Katalog-ID:	SPR036949566

Internformat


LEADER	01000caa a22002652 4500
001	SPR036949566
003	DE-627
005	20230328165955.0
007	cr uuu---uuuuu
008	201007s2019 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1007/s40318-019-00154-7 \|2 doi
035			\|a (DE-627)SPR036949566
035			\|a (SPR)s40318-019-00154-7-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
100	1		\|a Greene, Paul \|e verfasserin \|4 aut
245	1	0	\|a How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions
264		1	\|c 2019
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © T.M.C. Asser Instituut 2019
520			\|a Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care.
650		4	\|a Therapeutic Use Exemptions \|7 (dpeaa)DE-He213
650		4	\|a World Anti-Doping Code \|7 (dpeaa)DE-He213
650		4	\|a International Standard for Therapeutic Use Exemptions \|7 (dpeaa)DE-He213
650		4	\|a Ultimate Fighting Championship \|7 (dpeaa)DE-He213
650		4	\|a Retroactive TUE \|7 (dpeaa)DE-He213
650		4	\|a Prospective TUE \|7 (dpeaa)DE-He213
650		4	\|a Fairness \|7 (dpeaa)DE-He213
700	1		\|a Kaiser, Matthew \|0 (orcid)0000-0002-2234-917X \|4 aut
773	0	8	\|i Enthalten in \|t The international sports law journal \|d Berlin : Springer, 2002 \|g 19(2019), 1-2 vom: 12. Juli, Seite 29-37 \|w (DE-627)74670285X \|w (DE-600)2716249-7 \|x 2213-5154 \|7 nnns
773	1	8	\|g volume:19 \|g year:2019 \|g number:1-2 \|g day:12 \|g month:07 \|g pages:29-37
856	4	0	\|u https://dx.doi.org/10.1007/s40318-019-00154-7 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_184
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2070
912			\|a GBV_ILN_2086
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2116
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2122
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2472
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 19 \|j 2019 \|e 1-2 \|b 12 \|c 07 \|h 29-37

Indexfelder

author_variant	p g pg m k mk
matchkey_str	article:22135154:2019----::oaheergtcneetrrtceweicmsoeratvt
hierarchy_sort_str	2019
publishDate	2019
allfields	10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37
spelling	10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37
allfields_unstemmed	10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37
allfieldsGer	10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37
allfieldsSound	10.1007/s40318-019-00154-7 doi (DE-627)SPR036949566 (SPR)s40318-019-00154-7-e DE-627 ger DE-627 rakwb eng Greene, Paul verfasserin aut How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions 2019 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © T.M.C. Asser Instituut 2019 Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213 Kaiser, Matthew (orcid)0000-0002-2234-917X aut Enthalten in The international sports law journal Berlin : Springer, 2002 19(2019), 1-2 vom: 12. Juli, Seite 29-37 (DE-627)74670285X (DE-600)2716249-7 2213-5154 nnns volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37 https://dx.doi.org/10.1007/s40318-019-00154-7 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700 AR 19 2019 1-2 12 07 29-37
language	English
source	Enthalten in The international sports law journal 19(2019), 1-2 vom: 12. Juli, Seite 29-37 volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37
sourceStr	Enthalten in The international sports law journal 19(2019), 1-2 vom: 12. Juli, Seite 29-37 volume:19 year:2019 number:1-2 day:12 month:07 pages:29-37
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Therapeutic Use Exemptions World Anti-Doping Code International Standard for Therapeutic Use Exemptions Ultimate Fighting Championship Retroactive TUE Prospective TUE Fairness
isfreeaccess_bool	false
container_title	The international sports law journal
authorswithroles_txt_mv	Greene, Paul @@aut@@ Kaiser, Matthew @@aut@@
publishDateDaySort_date	2019-07-12T00:00:00Z
hierarchy_top_id	74670285X
id	SPR036949566
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036949566</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230328165955.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40318-019-00154-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036949566</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40318-019-00154-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Greene, Paul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© T.M.C. Asser Instituut 2019</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutic Use Exemptions</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">World Anti-Doping Code</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International Standard for Therapeutic Use Exemptions</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ultimate Fighting Championship</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Retroactive TUE</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prospective TUE</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fairness</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaiser, Matthew</subfield><subfield code="0">(orcid)0000-0002-2234-917X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The international sports law journal</subfield><subfield code="d">Berlin : Springer, 2002</subfield><subfield code="g">19(2019), 1-2 vom: 12. Juli, Seite 29-37</subfield><subfield code="w">(DE-627)74670285X</subfield><subfield code="w">(DE-600)2716249-7</subfield><subfield code="x">2213-5154</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1-2</subfield><subfield code="g">day:12</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:29-37</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40318-019-00154-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_184</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2019</subfield><subfield code="e">1-2</subfield><subfield code="b">12</subfield><subfield code="c">07</subfield><subfield code="h">29-37</subfield></datafield></record></collection>
author	Greene, Paul
spellingShingle	Greene, Paul misc Therapeutic Use Exemptions misc World Anti-Doping Code misc International Standard for Therapeutic Use Exemptions misc Ultimate Fighting Championship misc Retroactive TUE misc Prospective TUE misc Fairness How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions
authorStr	Greene, Paul
ppnlink_with_tag_str_mv	@@773@@(DE-627)74670285X
format	electronic Article
delete_txt_mv	keep
author_role	aut aut
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2213-5154
topic_title	How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions Therapeutic Use Exemptions (dpeaa)DE-He213 World Anti-Doping Code (dpeaa)DE-He213 International Standard for Therapeutic Use Exemptions (dpeaa)DE-He213 Ultimate Fighting Championship (dpeaa)DE-He213 Retroactive TUE (dpeaa)DE-He213 Prospective TUE (dpeaa)DE-He213 Fairness (dpeaa)DE-He213
topic	misc Therapeutic Use Exemptions misc World Anti-Doping Code misc International Standard for Therapeutic Use Exemptions misc Ultimate Fighting Championship misc Retroactive TUE misc Prospective TUE misc Fairness
topic_unstemmed	misc Therapeutic Use Exemptions misc World Anti-Doping Code misc International Standard for Therapeutic Use Exemptions misc Ultimate Fighting Championship misc Retroactive TUE misc Prospective TUE misc Fairness
topic_browse	misc Therapeutic Use Exemptions misc World Anti-Doping Code misc International Standard for Therapeutic Use Exemptions misc Ultimate Fighting Championship misc Retroactive TUE misc Prospective TUE misc Fairness
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	The international sports law journal
hierarchy_parent_id	74670285X
hierarchy_top_title	The international sports law journal
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)74670285X (DE-600)2716249-7
title	How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions
ctrlnum	(DE-627)SPR036949566 (SPR)s40318-019-00154-7-e
title_full	How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions
author_sort	Greene, Paul
journal	The international sports law journal
journalStr	The international sports law journal
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2019
contenttype_str_mv	txt
container_start_page	29
author_browse	Greene, Paul Kaiser, Matthew
container_volume	19
format_se	Elektronische Aufsätze
author-letter	Greene, Paul
doi_str_mv	10.1007/s40318-019-00154-7
normlink	(ORCID)0000-0002-2234-917X
normlink_prefix_str_mv	(orcid)0000-0002-2234-917X
title_sort	how athletes’ rights can be better protected when it comes to retroactive therapeutic use exemptions
title_auth	How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions
abstract	Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. © T.M.C. Asser Instituut 2019
abstractGer	Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. © T.M.C. Asser Instituut 2019
abstract_unstemmed	Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care. © T.M.C. Asser Instituut 2019
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_32 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_90 GBV_ILN_95 GBV_ILN_100 GBV_ILN_105 GBV_ILN_110 GBV_ILN_120 GBV_ILN_138 GBV_ILN_150 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_171 GBV_ILN_184 GBV_ILN_187 GBV_ILN_213 GBV_ILN_224 GBV_ILN_230 GBV_ILN_250 GBV_ILN_281 GBV_ILN_285 GBV_ILN_293 GBV_ILN_370 GBV_ILN_602 GBV_ILN_636 GBV_ILN_702 GBV_ILN_2001 GBV_ILN_2003 GBV_ILN_2004 GBV_ILN_2005 GBV_ILN_2006 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2009 GBV_ILN_2010 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2015 GBV_ILN_2020 GBV_ILN_2021 GBV_ILN_2025 GBV_ILN_2026 GBV_ILN_2027 GBV_ILN_2031 GBV_ILN_2034 GBV_ILN_2037 GBV_ILN_2038 GBV_ILN_2039 GBV_ILN_2044 GBV_ILN_2048 GBV_ILN_2049 GBV_ILN_2050 GBV_ILN_2055 GBV_ILN_2057 GBV_ILN_2059 GBV_ILN_2061 GBV_ILN_2064 GBV_ILN_2065 GBV_ILN_2068 GBV_ILN_2070 GBV_ILN_2086 GBV_ILN_2088 GBV_ILN_2093 GBV_ILN_2106 GBV_ILN_2107 GBV_ILN_2108 GBV_ILN_2110 GBV_ILN_2111 GBV_ILN_2112 GBV_ILN_2113 GBV_ILN_2116 GBV_ILN_2118 GBV_ILN_2119 GBV_ILN_2122 GBV_ILN_2129 GBV_ILN_2143 GBV_ILN_2144 GBV_ILN_2147 GBV_ILN_2148 GBV_ILN_2152 GBV_ILN_2153 GBV_ILN_2188 GBV_ILN_2190 GBV_ILN_2232 GBV_ILN_2336 GBV_ILN_2446 GBV_ILN_2470 GBV_ILN_2472 GBV_ILN_2507 GBV_ILN_2522 GBV_ILN_2548 GBV_ILN_4035 GBV_ILN_4037 GBV_ILN_4046 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4242 GBV_ILN_4246 GBV_ILN_4249 GBV_ILN_4251 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4326 GBV_ILN_4333 GBV_ILN_4334 GBV_ILN_4335 GBV_ILN_4336 GBV_ILN_4338 GBV_ILN_4393 GBV_ILN_4700
container_issue	1-2
title_short	How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions
url	https://dx.doi.org/10.1007/s40318-019-00154-7
remote_bool	true
author2	Kaiser, Matthew
author2Str	Kaiser, Matthew
ppnlink	74670285X
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.1007/s40318-019-00154-7
up_date	2024-07-03T20:30:29.395Z
_version_	1803591225859637248
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR036949566</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230328165955.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2019 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/s40318-019-00154-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR036949566</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s40318-019-00154-7-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Greene, Paul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© T.M.C. Asser Instituut 2019</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Therapeutic Use Exemptions (‘TUEs’) provide athletes a route to take prohibited substances for medically supported therapeutic reasons without violating anti-doping rules. They were instituted for the purpose of protecting an athlete’s right to medical care; however, the current retroactive TUE policy under the World Anti-Doping Program fails to uphold this right. In order to obtain a retroactive TUE, athletes are required to prove not only that they meet the criteria for obtaining a prospective TUE (i.e., their use of a prohibited substance or method is medically necessary and will not enhance their performance above a normal state of health) but also that their circumstances fall into one of four ‘exceptions’. The ‘fairness provision’—the last of the four exceptions—is the ‘catch-all’ provision that permits athletes to receive a retroactive TUE only if both the World Anti-Doping Agency (‘WADA’) and the relevant Anti-Doping Organization agree that fairness requires the grant of a retroactive TUE. Since its inception, this ‘fairness provision’ has been narrowly interpreted by TUE Committees, thus preventing athletes from avoiding anti-doping rule violations even in instances where they have met the test to obtain a prospective TUE. The Ultimate Fighting Championship’s (‘UFC’) TUE Policy, in contrast to WADA’s policy, more broadly permits athletes to obtain retroactive TUEs, in the end helping them avoid getting caught up in the anti-doping system. As the fourth edition of the WADA Code will be approved in the next year, we believe WADA stakeholders should consider a broader and more equitable use of the ‘fairness’ provision or adapt its policy to better protect all athletes’ right to medical care.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Therapeutic Use Exemptions</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">World Anti-Doping Code</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International Standard for Therapeutic Use Exemptions</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Ultimate Fighting Championship</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Retroactive TUE</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Prospective TUE</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Fairness</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaiser, Matthew</subfield><subfield code="0">(orcid)0000-0002-2234-917X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">The international sports law journal</subfield><subfield code="d">Berlin : Springer, 2002</subfield><subfield code="g">19(2019), 1-2 vom: 12. Juli, Seite 29-37</subfield><subfield code="w">(DE-627)74670285X</subfield><subfield code="w">(DE-600)2716249-7</subfield><subfield code="x">2213-5154</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:19</subfield><subfield code="g">year:2019</subfield><subfield code="g">number:1-2</subfield><subfield code="g">day:12</subfield><subfield code="g">month:07</subfield><subfield code="g">pages:29-37</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1007/s40318-019-00154-7</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_32</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_90</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_100</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_120</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_138</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_150</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_171</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_184</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_187</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_224</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_250</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_281</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_370</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_636</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_702</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2001</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2006</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2020</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2021</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2025</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2026</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2027</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2031</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2034</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2038</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2039</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2044</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2048</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2049</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2050</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2057</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2059</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2061</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2064</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2065</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2068</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2070</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2086</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2088</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2093</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2106</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2107</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2108</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2113</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2116</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2118</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2119</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2122</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2129</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2143</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2144</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2148</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2152</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2188</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2190</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2232</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2446</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2470</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2472</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2507</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2522</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2548</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4035</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4046</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4242</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4246</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4251</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4326</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4333</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4334</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4335</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4336</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4393</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">19</subfield><subfield code="j">2019</subfield><subfield code="e">1-2</subfield><subfield code="b">12</subfield><subfield code="c">07</subfield><subfield code="h">29-37</subfield></datafield></record></collection>
score	7.3981476

Nicht das Richtige dabei?

Schreiben Sie uns!

How athletes’ rights can be better protected when it comes to retroactive Therapeutic Use Exemptions

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?